AVENUE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.38 USD | -6.11% |
|
-1.74% | -72.01% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 159.9 | 99.64 | 5.544 | 2.133 | 3.18 | - | - |
| Enterprise Value (EV) 1 | 159.9 | 99.64 | 5.544 | 2.133 | 3.18 | 3.18 | 3.18 |
| P/E ratio | -5.82 x | -19.2 x | -0.71 x | -0.16 x | -0.01 x | -0.01 x | -0.02 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - |
| EV / FCF | - | - | - | -0.14 x | -0.24 x | -0.21 x | -0.16 x |
| FCF Yield | - | - | - | -695% | -419% | -488% | -634% |
| Price to Book | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 14.8 | 14.9 | 63.7 | 177 | 940.8 | - | - |
| Reference price 2 | 10,800 | 6,694 | 87.00 | 12.08 | 3.380 | 3.380 | 3.380 |
| Announcement Date | 3/30/20 | 3/31/21 | 3/30/23 | 3/18/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| EBIT 1 | -26.26 | -5.213 | -8.043 | -14.54 | -14.01 | -15.2 | -17.36 |
| Operating Margin | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -25.91 | -5.151 | - | -10.49 | -14.01 | -15.2 | -17.36 |
| Net income 1 | -25.91 | -5.151 | -3.552 | -10.38 | -14.01 | -15.2 | -17.36 |
| Net margin | - | - | - | - | - | - | - |
| EPS 2 | -1,856 | -348.8 | -122.3 | -73.50 | -430.5 | -249.8 | -213.8 |
| Free Cash Flow 1 | - | - | - | -14.83 | -13.31 | -15.5 | -20.17 |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 3/30/20 | 3/31/21 | 3/30/23 | 3/18/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -0.872 | - | -3.912 | -6.429 | -3.923 | -2.068 | -2.119 | -3.708 | -3.2 | -3.4 | -3.7 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -0.871 | - | - | - | - | - | 0.617 | -4.349 | -3.2 | -3.4 | -3.7 |
| Net income 1 | -0.871 | -0.662 | 0.575 | -7.536 | -4.007 | 0.526 | 0.64 | -4.34 | -3.2 | -3.4 | -3.7 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -56.25 | -33.75 | 92.25 | -102.8 | -39.00 | 4.500 | 42.00 | -15.40 | -78.75 | -83.25 | -90.75 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/15/21 | 11/10/22 | 3/30/23 | 5/10/23 | 8/10/23 | 11/13/23 | 3/18/24 | 5/15/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | - | -14.8 | -13.3 | -15.5 | -20.2 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - |
| Announcement Date | 3/30/20 | 3/31/21 | 3/30/23 | 3/18/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
3.38
USD
Average target price
900
USD
Spread / Average Target
+26,527.29%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -72.01% | 3.18M | |
| +18.72% | 125B | |
| +14.19% | 108B | |
| -4.93% | 24.21B | |
| +3.23% | 22.78B | |
| -10.44% | 17.96B | |
| -41.74% | 16.43B | |
| -13.31% | 16.37B | |
| +2.44% | 13.58B | |
| +27.89% | 11.66B |
- Stock Market
- Equities
- ATXI Stock
- Financials Avenue Therapeutics, Inc.
